TELA Bio, Inc. (TELA) |
| 0.9301 0.03 (3.31%) 05-29 15:07 |
| Open: | 0.8905 |
| High: | 0.97 |
| Low: | 0.89 |
| Volume: | 53,371 |
| Market Cap: | 42(M) |
| PE Ratio: | -1.12 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 1.27 |
| Resistance 1: | 1.02 |
| Pivot price: | 0.92 |
| Support 1: | 0.62 |
| Support 2: | 0.52 |
| 52w High: | 2.2 |
| 52w Low: | 0.501 |
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
| EPS | -0.790 |
| Book Value | 0.140 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.222 |
| Profit Margin (%) | -49.30 |
| Operating Margin (%) | -55.23 |
| Return on Assets (ttm) | -28.7 |
| Return on Equity (ttm) | -616.6 |
Thu, 28 May 2026
Canaccord Genuity Maintains TELA Bio (TELA) Buy Recommendation - MSN
Tue, 26 May 2026
TELA Bio | 8-K: Current report - Moomoo
Tue, 26 May 2026
TELA Stock Price, Quote & Chart | TELA BIO INC (NASDAQ:TELA) - ChartMill
Wed, 13 May 2026
TELA Bio, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Wed, 13 May 2026
TELA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Tue, 12 May 2026
TELA Bio (NASDAQ: TELA) Q1 2026 revenue rises 3% to $19.1M - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |